Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

INTRODUCTION: At the time when metastatic disease is identified, assessment of human epidermal growth factor receptor (HER)2 status might help to optimize treatment decisions if HER2 status was not determined at first diagnosis and if HER2 positivity has been acquired during disease progression. Wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehm, Tanja, Becker, Sven, Duerr-Stoerzer, Silke, Sotlar, Karl, Mueller, Volkmar, Wallwiener, Diethelm, Lane, Nancy, Solomayer, Erich, Uhr, Jonathan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242672/
https://www.ncbi.nlm.nih.gov/pubmed/17963511
http://dx.doi.org/10.1186/bcr1783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242672/
https://www.ncbi.nlm.nih.gov/pubmed/17963511
http://dx.doi.org/10.1186/bcr1783

Ejemplares similares